Glucagon-Like Peptide-1 Receptor Agonists: Considerations for Treating Preconception Obesity

A new way to define obesity aims to sharpen the diagnosis. Critics warn it could delay care, exclude diabetes, and deepen inequities in accessing treatment.

Abstract. The Lancet Diabetes & Endocrinology Commission undertook the complex task of addressing limitations in existing definitions and classificatio

DXA-derived estimates of abdominal adiposity in postmenopausal women may allow for substantially improved risk prediction of diabetes over standard clinical risk models. Larger DXA studies with…

In this special edition of Diabetes Core Update we present a special podcast recorded live at the ADA Scientific Sessions by the editors of Diabetes Core Update, Diabetes Care On Air, Diabetes Bio,…

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination therapy might change that.

Maridebart cafraglutide (known as MariTide) is a long-acting peptide–antibody conjugate that combines glucagon-like peptide-1 receptor agonism and glucose-dependent insulinotropic polypeptide recep...

Adrenocortical carcinoma is a rare endocrine malignancy. The management of patients with adrenocortical carcinoma is challenging for several reasons, including its heterogeneous but frequently aggress...

IcoSema and the evolution of fixed-ratio insulin-GLP-1 receptor agonist therapies